Navigation Links
Chiltern Announces Collaboration With Dr Nawab Qizilbash
Date:12/17/2009

LONDON, Dec. 17 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, is pleased to announce our collaboration with Dr Nawab Qizilbash of OXON Epidemiology.

Dr Nawab Qizilbash, MBChB BSc MRCP (UK) MSc Phil (Oxon) is the Director of OXON Epidemiology Ltd. He served as Director of Epidemiology and Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University, Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase IV trials and meta-analysis. He also collaborates with Professor Stephen Evans in academic research on statistical signal detection. Dr Qizilbash has authored 5 publications in the Lancet, 1 in the Journal of the American Medical Association and 1 in the British Medical Journal, among others. He founded the Cochrane Dementia Group and is chief editor of an international textbook on clinical dementia.

Jane Turner, MRPharmS, Chiltern's Late Phase Director, Europe, stated, "We are delighted to announce the alliance between Chiltern Late Phase and Dr Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche consultancy company that specializes in 'real world data': epidemiology, risk management and health economics. This partnership will allow Chiltern to provide epidemiology and outcomes research expertise in conjunction with flexible and bespoke late phase study solutions to our sponsors. Steve Albrecht, Global head of Chiltern Late Phase, added, "We are excited about this ongoing collaboration which significantly strengthens Chiltern's global service offering in epidemiology, pharmacoeconomics and risk management.

Dr Qizilbash commented, "OXON is delighted to be collaborating with Chiltern Late Phase. The combination provides scientific strength with breadth and global reach to late phase, allowing for strategic consulting, planning and implementation of: observational studies, risk management, health economics and Phase IV trials."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 29 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.


    For More Information:

    Natalie Chong, Chiltern International Ltd.
    171 Bath Road
    Slough, Berkshire SL1 4AA, UK
    Tel:  44 (0) 1753 512 000
    Email: natalie.chong@chiltern.com

    Sue Ojanen, Chiltern International Inc.
    1241 Volunteer Parkway
    Bristol, TN 37620, USA
    Tel:  1 (423) 968 9533
    Email: sue.ojanen@chiltern.com

SOURCE Chiltern


'/>"/>
SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology: